Global collaborations

Dejan Radjeski; Eliza Hawke; Owen A. O'Connor; Pier Luigi Zinzani; Won Seog Kim; Enrica Marchi

doi:10.1002/9781119671336.ch28

Global collaborations

Dejan Radjeski, Eliza Hawke, Owen A. O'Connor, Pier Luigi Zinzani, Won Seog Kim, Enrica Marchi

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

If the upper incidence of the most common form of peripheral T-cell lymphoma (PTCL), namely PTCL not otherwise specified, is 2500 cases/year, then one medical oncologist would expect to see a case every six years. Every meeting on PTCL shares a common message: we need to stop relying on anecdotes, small series of patients, and retrospective collections of information to decide what is best for patients. The Global T-Cell Lymphoma Consortium, not yet at full steam, has been launched and is now functioning. The mission of the Consortium is to provide a comprehensive network of clinical centers and principal investigators with specialized expertise in T-cell lymphoma. It is well accepted that one of the major barriers in the development of meaningful advances in PTCL relates to the timeline necessary to conduct important clinical research.

Original language	English
Title of host publication	The Peripheral T-Cell Lymphomas
Publisher	wiley
Pages	379-384
Number of pages	6
ISBN (Electronic)	9781119671336
ISBN (Print)	9781119671312
DOIs	https://doi.org/10.1002/9781119671336.ch28
State	Published - 19 Feb 2021
Externally published	Yes

Keywords

Clinical research
Global T-Cell Lymphoma Consortium
Medical oncologist
Peripheral T-cell lymphoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/9781119671336.ch28

Cite this

@inbook{5e3d545c52ce4303be93bdeee7977eb4,

title = "Global collaborations",

abstract = "If the upper incidence of the most common form of peripheral T-cell lymphoma (PTCL), namely PTCL not otherwise specified, is 2500 cases/year, then one medical oncologist would expect to see a case every six years. Every meeting on PTCL shares a common message: we need to stop relying on anecdotes, small series of patients, and retrospective collections of information to decide what is best for patients. The Global T-Cell Lymphoma Consortium, not yet at full steam, has been launched and is now functioning. The mission of the Consortium is to provide a comprehensive network of clinical centers and principal investigators with specialized expertise in T-cell lymphoma. It is well accepted that one of the major barriers in the development of meaningful advances in PTCL relates to the timeline necessary to conduct important clinical research.",

keywords = "Clinical research, Global T-Cell Lymphoma Consortium, Medical oncologist, Peripheral T-cell lymphoma",

author = "Dejan Radjeski and Eliza Hawke and O'Connor, \{Owen A.\} and Zinzani, \{Pier Luigi\} and Kim, \{Won Seog\} and Enrica Marchi",

note = "Publisher Copyright: {\textcopyright} 2021 John Wiley \& Sons Ltd.",

year = "2021",

month = feb,

day = "19",

doi = "10.1002/9781119671336.ch28",

language = "English",

isbn = "9781119671312",

pages = "379--384",

booktitle = "The Peripheral T-Cell Lymphomas",

publisher = "wiley",

}

TY - CHAP

T1 - Global collaborations

AU - Radjeski, Dejan

AU - Hawke, Eliza

AU - O'Connor, Owen A.

AU - Zinzani, Pier Luigi

AU - Kim, Won Seog

AU - Marchi, Enrica

PY - 2021/2/19

Y1 - 2021/2/19

N2 - If the upper incidence of the most common form of peripheral T-cell lymphoma (PTCL), namely PTCL not otherwise specified, is 2500 cases/year, then one medical oncologist would expect to see a case every six years. Every meeting on PTCL shares a common message: we need to stop relying on anecdotes, small series of patients, and retrospective collections of information to decide what is best for patients. The Global T-Cell Lymphoma Consortium, not yet at full steam, has been launched and is now functioning. The mission of the Consortium is to provide a comprehensive network of clinical centers and principal investigators with specialized expertise in T-cell lymphoma. It is well accepted that one of the major barriers in the development of meaningful advances in PTCL relates to the timeline necessary to conduct important clinical research.

AB - If the upper incidence of the most common form of peripheral T-cell lymphoma (PTCL), namely PTCL not otherwise specified, is 2500 cases/year, then one medical oncologist would expect to see a case every six years. Every meeting on PTCL shares a common message: we need to stop relying on anecdotes, small series of patients, and retrospective collections of information to decide what is best for patients. The Global T-Cell Lymphoma Consortium, not yet at full steam, has been launched and is now functioning. The mission of the Consortium is to provide a comprehensive network of clinical centers and principal investigators with specialized expertise in T-cell lymphoma. It is well accepted that one of the major barriers in the development of meaningful advances in PTCL relates to the timeline necessary to conduct important clinical research.

KW - Clinical research

KW - Global T-Cell Lymphoma Consortium

KW - Medical oncologist

KW - Peripheral T-cell lymphoma

UR - https://www.scopus.com/pages/publications/85147946512

U2 - 10.1002/9781119671336.ch28

DO - 10.1002/9781119671336.ch28

M3 - Chapter

AN - SCOPUS:85147946512

SN - 9781119671312

SP - 379

EP - 384

BT - The Peripheral T-Cell Lymphomas

PB - wiley

ER -

Global collaborations

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this